Novo Nordisk has slashed Wegovy’s cash price to $349 a month and most Ozempic doses to the same level, undercutting rivals as CEO Mike Doustdar pledges to go “all in” on weight-loss pills. The move, paired with a $199 introductory offer, intensifies competition with Eli Lilly and expands access ahead of Trump-era pricing reforms.